Optimized high-dose amoxicillin–proton-pump inhibitor dual therapies fail to achieve high cure rates in China

• Published in: Saudi journal of gastroenterology Vol. 23; no. 5; pp. 275 - 280
• Main Authors: Hu, Jia-Li, Yang, Jun, Zhou, Yin-Bin, Li, Ping, Han, Ran, Fang, Dian-Chun
• Format: Journal Article
• Language: English
• Published: India Medknow Publications and Media Pvt. Ltd 01.09.2017; Medknow Publications & Media Pvt. Ltd; Medknow Publications & Media Pvt Ltd; Wolters Kluwer Medknow Publications
• Subjects: Acids; Adult; Amoxicillin; Amoxicillin - administration & dosage; Amoxicillin - pharmacokinetics; Amoxicillin - pharmacology; Analysis; Anti-Bacterial Agents - administration & dosage; Antibiotics; Bismuth; Bismuth - administration & dosage; bismuth-containing quadruple regimen; Breath Tests - methods; Care and treatment; China - epidemiology; Clarithromycin - administration & dosage; Comparative analysis; Dosage and administration; Drug Administration Schedule; Drug dosages; Drug resistance; Drug therapy; Drug Therapy, Combination - methods; dual therapy; eradication rate; Female; Gastritis - diagnosis; Gastritis - drug therapy; Gastritis - microbiology; Gastroenterology; Gastrointestinal diseases; Health aspects; Helicobacter infections; Helicobacter Infections - diagnosis; Helicobacter Infections - drug therapy; Helicobacter pylori; Helicobacter pylori - drug effects; Hospitals; Humans; Infections; Laboratories; Male; Meals; Middle Aged; Morphology; Original; Patients; Penicillin; Peptic Ulcer - diagnosis; Peptic Ulcer - drug therapy; Peptic Ulcer - microbiology; Proton pump inhibitors; Proton Pump Inhibitors - administration & dosage; Proton Pump Inhibitors - pharmacokinetics; Proton Pump Inhibitors - pharmacology; Rabeprazole - administration & dosage; Rabeprazole - pharmacokinetics; Rabeprazole - pharmacology; Studies; Treatment Outcome; Ulcers; China
• ISSN: 1319-3767; 1998-4049; 1998-4049
• DOI: 10.4103/sjg.SJG_91_17

Background\Aim: Quadruple daily administration of proton-pump inhibitor (PPI) therapy achieves potent acid inhibition, and combined with amoxicillin, with its pharmacodynamic and pharmacokinetic characteristics, may be efficient for Helicobacter pylori eradication. We compared the efficacy of two optimized high-dose dual therapies with a bismuth-containing quadruple regimen for treating H. pylori infection. Rabeprazole dosages for H. pylori eradication were also evaluated. Treatment-naive and H. pylori-positive subjects were recruited and randomly apportioned to three treatment groups: Group A (n = 87), rabeprazole 10 mg plus amoxicillin 750 mg (4 times/day for 14 days); Group B (n = 87), rabeprazole 20 mg plus amoxicillin 750 mg (4 times/day for 14 days); and Group C (n = 89), bismuth-containing quadruple regimen consisting of rabeprazole 20 mg, bismuth 220 mg, amoxicillin 1000 mg, and clarithromycin 500 mg (2 times/day for 14 days). Four weeks after treatment discontinuation, patients were examined for H. pylori infection by 13C-urea breath test. The rates of adverse effects, compliance, and eradication were evaluated. Eradication rates in groups A, B, and C were 78.1, 81.6, and 84.3%, respectively, based on intention-to-treat analysis, or 79.1, 83.5, and 86.2%, according to per-protocol analysis. Rates of adverse events and compliance of the three groups were similar. For treating H. pylori infection, optimized high-dose amoxicillin-PPI dual therapies failed to achieve high cure rates in China and held no advantage over a bismuth-containing quadruple regimen.